- Inappropriate use of one of Solvay products in a customer’s plant, or use in applications or markets for which the product is not designed (inappropriate use), or use by the customer that is not endorsed by Solvay can lead to adverse health and environmental impacts, property damage, and resulting litigation.
- The possible consequences of a faulty product include exposure to liability for injury, health impairment and damage, or product recalls. Product liability risk is generally higher for products used in medical devices, healthcare, food contact and feed applications, and sensitive applications in general.
- The inadvertent use or sale of substances that are banned by regulations may occur. In Europe the focus is on Substances of Very High Concern (SVHC).
- Failure to comply with chemical and market regulations in countries where a product is marketed could have negative consequences.
Prevention and mitigations actions
- Solvay Safety Data Sheets (SDS) ensure harmonized content by implementing a common worldwide SAP system for the Group. This SAP system is, however, not yet implemented for Composite Materials; the go-live for this GBU is planned for beginning 2020.
- In particular for SVHC, according to Solvay definition, all GBU perform an annual inventory of those substances in the products they sell. The objective is to have 100% risk assessment and analysis of any available safer alternatives by 2020.
- SDS are constantly maintained and distributed worldwide for all products to all customers in the appropriate languages. Global Business Units ensure that SDS are revised at least every three years for all the products they sell.
- Recall procedures are developed and deployed as prescribed by the product stewardship programs.
- Insurance reduces the financial impact of a product liability risk, including for first-party and third-party product recalls.
2019 main actions
The Solvay “Product Safety Management Process” (PSMP) identifies risks relating to products marketed by Solvay. It has been updated to integrate new regulatory requirements and additional potential risk causes (legal, supply chain, etc.). All GBUs are currently implementing this process with a specific focus on prioritizing the required risk assessments in the products portfolio and on regularly deploying risk assessments for the most sensitive product applications.